Results 241 to 250 of about 436,450 (285)

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Barriers and Facilitators to Accessing and Using Maternal Healthcare Services by Women Living in Rural Bangladesh: A Theory-Guided Narrative Literature Review. [PDF]

Public Health Rev
Chanda SK, McHugh GA, Horne M.
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p/SPP/MHC-I Axis. [PDF]

Adv Sci (Weinh)
Wang M, Sun M, Dong H, Zhang X, Zhang J, Zhang Z, Ni M, Li L, Pei Y, Chen X, Li Q, Bu F, Huang J, Jiang L, Fang Z, Chen X, Chen J, Qiao Y, Xie T.   +18 more
europepmc   +1 more source

RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or without CD3 mRNA. [PDF]

Exp Hematol Oncol
Campillo-Davo D, Flumens D, Berneman ZN, Fujiki F, Roex G, Versteven M, Van Acker HH, Van Tendeloo VFI, Sugiyama H, Anguille S, Lion E.   +10 more
europepmc   +1 more source

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. [PDF]

J Immunother Cancer
Roulstone V, Kyula J, Appleton E, Bommareddy PK, Patrikeev A, Jones S, Kuncheria L, Chan Wah Hak CM, Foo S, Baldock H, Wongariyapak A, Leslie I, Pickering R, Zierhut C, Smith HG, Mohan N, Murano C, Hubbard LC, Dean I, Patin EC, Gkantalis J, Mansfield D, Pedersen M, McLaughlin M, Goicoechea M, Layzell S, Mannion J, Fernando W, Meier P, Vile R, Melcher A, Coffin RS, Harrington KJ.   +32 more
europepmc   +1 more source

Transforming specialized mental health practice: Insights from clients' perspectives on how to support recovery. [PDF]

PLOS Ment Health
Lorenz-Artz K, Bierbooms J, Bongers I.
europepmc   +1 more source

Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG). [PDF]

Neoplasia
Khairkhah N, Owolabi H, Namvar A, Ibrahim MMH, Nyayapathy S, Jones R, Rumble JM, Whitehead CE, Sebolt-Leopold JS, Everest-Dass A, Galban S.   +10 more
europepmc   +1 more source